Senzer to launch first inhaled cannabinoids in UK

5 July 2018
marijuana_cannabis_cbd_thc_big

Senzer, a privately-held British firm, has announced its intention to launch its portfolio of inhaled cannabinoid therapies in the UK.

First to launch in the UK will be Cannafen (cannabidiol), followed by Candex (dronabinol) in early 2019. Both drugs are adminstered via Senzer's unique inhaler system.

"Our delivery technology is a first of its kind — a respiratory delivery system that uses a breath-operated valve technology and delivers pharmaceutical grade cannabinoids rapidly into the bloodstream," said Alex Hearn, chief executive of Senzer.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical